Novo Nordisk Says Semaglutide Cut BMI in Children Under 12

Novo Nordisk reported first results from the STEP Young phase 3 trial, saying once-weekly semaglutide combined with a reduced-calorie diet and more physical activity produced superior BMI reduction at week 68 in children aged 6 to under 12 years old with obesity.

Novo Nordisk has reported the first results from STEP Young, a phase 3 trial of once-weekly semaglutide in children aged 6 to under 12 years old with obesity. The company said the treatment, given alongside a reduced-calorie diet and increased physical activity, delivered superior reduction in body mass index at week 68.

That single sentence carries more weight than its brevity suggests. Until now, the commercial and clinical story of semaglutide in younger patients has centred on adolescents. Extending a randomised phase 3 readout down to primary-school age moves the drug into a population where treatment options are almost entirely behavioural, where families and paediatricians are cautious, and where regulators scrutinise every safety signal with particular care.

What STEP Young actually tested

The trial evaluated once-weekly semaglutide in combination with lifestyle intervention — a reduced-calorie diet and increased physical activity — rather than as a standalone therapy. That design detail matters for how any eventual label would read: the comparison is drug-plus-lifestyle against lifestyle alone, which is the standard framework in paediatric obesity research and the one clinicians would follow in practice.

The primary endpoint was assessed at week 68, the same 68-week horizon Novo Nordisk has used across the broader STEP programme in adults and adolescents. Keeping the duration consistent makes cross-trial comparison easier for regulators and for physicians reading the eventual publication.

In children, the efficacy measure itself differs from adult trials. Adults are assessed on percentage change in body weight. Children are still growing, so weight loss alone is a poor yardstick; BMI, or a BMI measure indexed to age and sex norms, is used instead. Novo Nordisk's statement that the BMI reduction was superior is therefore the relevant efficacy claim, and it is the one the company chose to lead with.

Beyond that, the company's initial announcement, reported by Nasdaq Markets, is a topline disclosure. The detailed magnitude of effect, the safety and tolerability profile, discontinuation rates and any effect on growth and development are the numbers that will decide how this data is received — and those come with the full presentation and peer-reviewed publication, not the press release.

Why a 6-to-under-12 readout is a different proposition

Paediatric obesity is one of the few areas of metabolic medicine where the standard of care has barely changed in a generation. Guidance centres on diet, activity and family-based behavioural programmes, with pharmacotherapy reserved for older children and surgery for a narrow group of severe cases. A drug with a randomised phase 3 result in children as young as six would be a genuine addition to that toolkit if the safety data hold up.

It is also where the resistance will be loudest. Prescribing a chronic injectable metabolic drug to a six-year-old raises questions that do not arise in adults: how long treatment continues, what happens on withdrawal, whether growth trajectories and nutritional intake are affected, and how families weigh a lifelong condition against a lifelong medication. Those are the questions payers and paediatric societies will ask, and they are answered by longer-term follow-up rather than by a 68-week endpoint.

For Novo Nordisk, the strategic logic is straightforward. The company has spent years widening semaglutide's evidence base across indications and age brackets, on the view that obesity is best treated as a chronic disease with a long treatment horizon. Each new population that produces positive phase 3 data both extends the addressable market and deepens the clinical case that obesity medicines belong in mainstream primary care.

Where the shares sit as the data lands

Novo Nordisk trades across three listings named in the company's disclosure: NVO in the United States, NOVOB.CO in Copenhagen and NOV.DE in Germany. In the most recent session for which licensed data is available, NVO last traded at 46.61, down 1.89% from a prior close of 47.51, having moved within a session range of 46.04 to 46.74. That is the last trade as of 20:00 GMT on Friday, 4 September 2026; markets were closed at the time of writing, and the price is a close rather than a live quote. The currency of that quote is not specified in the data supplied here.

The wider tape into that close was mixed rather than directional. The S&P 500 tracker SPY finished at $770.23, off 0.38% from $773.17. The Dow proxy DIA closed at $534.12, down 0.52%. The Nasdaq 100 tracker QQQ was the outlier on the upside at $719.00, up 0.19% from $717.67. In other words, the backdrop offers no single macro explanation for the move in Novo Nordisk shares, and the STEP Young topline was disclosed after that session.

The questions the full dataset has to answer

Three things determine whether this readout becomes a regulatory filing or a footnote.

• Safety and tolerability in young children. Gastrointestinal side effects dominate the adult experience with GLP-1 medicines. How they translate to a six-to-eleven-year-old cohort, and what share of participants stopped treatment, will be central.
• Effect on growth and development. Regulators reviewing any paediatric metabolic drug will want reassurance that reducing BMI has not come at the cost of normal growth, bone development or nutritional adequacy.
• Durability and what follows treatment. A week-68 endpoint is a snapshot. The clinical debate over obesity medicines has consistently turned on what happens when treatment stops, and that debate is sharper still when the patient is a child.

Also unresolved is the commercial path. A positive trial does not by itself create a reimbursed paediatric indication; that requires a regulatory submission, a label negotiation and payer coverage decisions, each of which can take considerably longer than the trial itself. Investors watching Novo Nordisk should treat STEP Young as an incremental expansion of the semaglutide evidence base rather than a near-term revenue event.

What to watch next: the full data presentation and publication, including the size of the BMI effect and the safety tables; any statement from Novo Nordisk on regulatory filing plans in the United States and Europe; and the reaction of paediatric clinical bodies, whose guidance will shape uptake far more than marketing will.

Key facts

• Trial: STEP Young, phase 3, once-weekly semaglutide plus reduced-calorie diet and increased physical activity
• Population: Children aged 6 to under 12 years old with obesity
• Primary result: Superior BMI reduction at week 68
• Share price: NVO last traded at 46.61, -1.89%, as of 20:00 GMT, 4 Sep 2026 (market closed)

Frequently asked questions

What did the STEP Young trial find?

Novo Nordisk said first results from the STEP Young phase 3 trial showed superior reduction in body mass index at week 68 among children aged 6 to under 12 years old with obesity. Participants received once-weekly semaglutide alongside a reduced-calorie diet and increased physical activity. The company's initial disclosure was topline; the magnitude of effect and safety detail come with the full presentation.

Why does the trial measure BMI rather than weight loss?

Children are still growing, so absolute or percentage weight change is a poor measure of treatment effect. Paediatric obesity trials instead use body mass index, typically indexed to age and sex norms, so that changes reflect body composition relative to normal development rather than the growth that would occur anyway.

Does this mean semaglutide will be approved for young children?

Not automatically. A positive phase 3 result is the evidence base for a regulatory submission, not an approval. Novo Nordisk would need to file with regulators such as the FDA and the European Medicines Agency, agree a label, and then secure payer coverage. Each step takes time, and safety data in young children will be scrutinised closely.

Why is week 68 the endpoint?

Novo Nordisk has used a 68-week assessment across the broader STEP clinical programme, including trials in adults and adolescents. Keeping the duration consistent lets regulators and clinicians compare results across populations more easily. It also captures a period long enough for the treatment effect to plateau rather than reflecting only early weight change.

How did Novo Nordisk shares perform ahead of the announcement?

In the last session for which licensed data is available, the NVO listing closed at 46.61, down 1.89% from a prior close of 47.51, within a range of 46.04 to 46.74. That was as of 20:00 GMT on 4 September 2026. Markets were closed, so this is a last traded price rather than a live quote.

What are the main open questions from the readout?

Three: the safety and tolerability profile in children as young as six, including gastrointestinal side effects and discontinuation rates; whether reducing BMI affects normal growth and development; and what happens after treatment stops, since durability has been the central clinical debate around obesity medicines in adults.

Sources

• Novo Nordisk: STEP Young Phase 3 Trial With Semaglutide Shows Superior BMI Reduction At Week 68 — Nasdaq Markets

Photo: Los Muertos Crew · Pexels Licence — source